On November 15, our friends at CureTalks will hold a telecon on which there will be a discussion about the current and potential future uses of CAR-T in the treatment of cancer with Prof. Carl June of the University of Pennsylvania. … READ MORE …
Filed under: Drugs in development | Tagged: antigen, CAR-T, chimeric, receptor, T-cell, therapy | Leave a comment »
As yet, there has been no serious clinical exploration of whether the new types of CAR-T treatment can be applied to patients with either prostate cancer or any other form of solid tumor. … READ MORE …
Filed under: Drugs in development | Tagged: antigen, CAR-T, chimeric, receptor, therapy | 2 Comments »
Xofigo® (radium Ra-223 dichoride) has been a game-changer in the treatment of prostate cancer metastatic to bone. Not only does it provide significant pain palliation and reduce skeletal-related adverse events, but it slows down progression of the disease, increasing median survival by about 30 percent. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: antigen, J591, Lu-177, lutetium, membrane, PSMA, radiation, surface, systemic | 19 Comments »
An article in today’s issue of the New England Journal of Medicine reports data from a Phase II trial of CART therapy in the treatment of patients with acute lymphoblastic leukemia or ALL (an aggressive and difficult to treat form of cancer). This is arguably one of the most exciting papers on the treatment of cancer in the past 50+ years. … READ MORE …
Filed under: Uncategorized | Tagged: antigen, CART, chimeric, CTL019, leukemia, T-cell | Leave a comment »
A research team at the University of Miami has come up with an innovative new method that (please note the emphasis) might offer a completely new way to eliminate remaining cancer cells in patients with prostate and other types of cancer after first-line therapy. … READ MORE …
Filed under: Drugs in development | Tagged: antigen, cancer cell, expression, immunity, tumor | Leave a comment »
